These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 28687071)

  • 1. Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.
    Darcis G; Van der Auwera G; Giot JB; Hayette MP; Tassin F; Arrese Estrada J; Cnops L; Moutschen M; de Leval L; Leonard P
    BMC Infect Dis; 2017 Jul; 17(1):478. PubMed ID: 28687071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leishmaniasis.
    Herwaldt BL
    Lancet; 1999 Oct; 354(9185):1191-9. PubMed ID: 10513726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review.
    Trindade MA; Silva LL; Braz LM; Amato VS; Naafs B; Sotto MN
    BMC Infect Dis; 2015 Nov; 15():543. PubMed ID: 26592919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
    Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
    Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leishmaniasis in immunosuppressed individuals.
    van Griensven J; Carrillo E; López-Vélez R; Lynen L; Moreno J
    Clin Microbiol Infect; 2014 Apr; 20(4):286-99. PubMed ID: 24450618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure.
    Eichenberger A; Buechi AE; Neumayr A; Hatz C; Rauch A; Huguenot M; Diamantis-Karamitopoulou E; Staehelin C
    BMC Infect Dis; 2017 Jan; 17(1):81. PubMed ID: 28095796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous leishmaniasis treatment.
    Minodier P; Parola P
    Travel Med Infect Dis; 2007 May; 5(3):150-8. PubMed ID: 17448941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-kala-azar dermal leishmaniasis due to Leishmania infantum in an HIV-negative patient treated with miltefosine.
    Monge-Maillo B; Norman FF; Chamorro-Tojeiro S; Gioia F; Pérez-Molina JA; Chicharro C; Moreno J; López-Vélez R
    J Travel Med; 2022 Nov; 29(7):. PubMed ID: 34668558
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful Treatment of Disseminated Cutaneous Leishmaniasis With Liposomal Amphotericin B and Miltefosine in an Eight-year-old Girl.
    Hamzavi SS; Sanaei Dashti A; Kadivar MR; Pouladfar G; Pourabbas B
    Pediatr Infect Dis J; 2018 Mar; 37(3):275-277. PubMed ID: 29424815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
    Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
    J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation of Leishmania tropica from a patient with visceral leishmaniasis and disseminated cutaneous leishmaniasis, southern Iran.
    Alborzi A; Pouladfar GR; Fakhar M; Motazedian MH; Hatam GR; Kadivar MR
    Am J Trop Med Hyg; 2008 Sep; 79(3):435-7. PubMed ID: 18784238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
    Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
    Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
    [No Abstract]   [Full Text] [Related]  

  • 13. Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.
    Pandey BD; Pandey K; Kaneko O; Yanagi T; Hirayama K
    Am J Trop Med Hyg; 2009 Apr; 80(4):580-2. PubMed ID: 19346379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current scenario of drug development for leishmaniasis.
    Croft SL; Seifert K; Yardley V
    Indian J Med Res; 2006 Mar; 123(3):399-410. PubMed ID: 16778319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent dermal lesions in a patient with previous history of visceral leishmaniasis.
    Jaiteh MB; İnkaya AÇ; Üner A; Elçin G; Ergüven S; Kurtulan O; Harxhi A; Akova M
    Parasitol Int; 2021 Feb; 80():102197. PubMed ID: 32920054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial.
    Sundar S; Sinha PK; Rai M; Verma DK; Nawin K; Alam S; Chakravarty J; Vaillant M; Verma N; Pandey K; Kumari P; Lal CS; Arora R; Sharma B; Ellis S; Strub-Wourgaft N; Balasegaram M; Olliaro P; Das P; Modabber F
    Lancet; 2011 Feb; 377(9764):477-86. PubMed ID: 21255828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leishmaniasis: an update of current pharmacotherapy.
    Sundar S; Chakravarty J
    Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of
    Özbilgin A; Çavuş İ; Kaya T; Yıldırım A; Harman M
    Turkiye Parazitol Derg; 2020 Mar; 44(1):12-16. PubMed ID: 32212583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The treatment of visceral leishmaniasis: safety and efficacy.
    Jha RK; Sah AK; Shah DK; Sah P
    JNMA J Nepal Med Assoc; 2013; 52(192):645-51. PubMed ID: 25327244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpected diagnosis of basal cell carcinoma in a patient presenting with a secondary location of
    Ben Abda I; Ben-Abdallah R; Hammami H; Ben Abid M; Mdimagh-Kchir H; Bahri K; Siala E; Aoun K; Bouratbine A
    Pan Afr Med J; 2019; 34():8. PubMed ID: 31762877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.